CFO interim
Keros Therapeutics, Inc. names Annita Tanini interim CFO
Keros Therapeutics, Inc. reported in a Form 8-K filed July 22, 2026 that Annita Tanini was named interim interim principal financial officer and principal accounting officer, effective August 4, 2026.
In the filing's words
On July 17, 2026, Keith Regnante resigned from his role as Chief Financial Officer of Keros Therapeutics, Inc. (the “Company”), effective August 3, 2026 (the “Separation Date”), to pursue other opportunities.
Verbatim from sec.gov, Item 5.02. We quote departures; we do not characterize them.
| Company | Keros Therapeutics, Inc. (KROS) |
|---|---|
| Event | Interim |
| Incoming | Annita Tanini |
| Outgoing | Keith Regnante |
| Title in the filing | interim principal financial officer and principal accounting officer |
| Effective | August 4, 2026 |
| 8-K filed | July 22, 2026 |
| Internal promotion | Yes |
| Prior role (per filing) | Corporate Controller and Vice President, Finance, Keros Therapeutics, Inc. |
| SEC CIK | 0001664710 |
Keros Therapeutics, Inc. reported this change in a Form 8-K, Item 5.02, filed July 22, 2026. The filing's own words are quoted above.
Sources
- sec.gov · SEC filing, Item 5.02 · accessed 2026-09-26
Something wrong about Annita Tanini? Send a correction with the primary source.